SEARCH

SEARCH BY CITATION

References

  • Ballen, K.K. & Barker, J.N. (2013) Has umbilical cord blood transplantation for AML become mainstream? Current Opinion in Hematology, 20, 144149.
  • van Besien, K., Dew, A., Lin, S., Joseph, L., Godley, L.A., Larson, R.A., Odenike, T., Rich, E., Stock, W., Wickrema, A. & Artz, A.S. (2009) Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leukaemia & Lymphoma, 50, 18091817.
  • Boeckh, M., Gooley, T.A., Myerson, D., Cunningham, T., Schoch, G. & Bowden, R.A. (1996) Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood, 88, 40634071.
  • Brunstein, C.G., Gutman, J.A., Weisdorf, D.J., Woolfrey, A.E., Defor, T.E., Gooley, T.A., Verneris, M.R., Appelbaum, F.R., Wagner, J.E. & Delaney, C. (2010) Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 116, 46934699.
  • Brunstein, C.G., Fuchs, E.J., Carter, S.L., Karanes, C., Costa, L.J., Wu, J., Devine, S.M., Wingard, J.R., Aljitawi, O.S., Cutler, C.S., Jagasia, M.H., Ballen, K.K., Eapen, M. & O'Donnell, P.V. (2011) Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood, 118, 282288.
  • Carpenter, B., Haque, T., Dimopoulou, M., Atkinson, C., Roughton, M., Grace, S., Denovan, S., Fielding, A., Kottaridis, P.D., Griffiths, P., Mackinnon, S., Emery, V. & Chakraverty, R. (2010) Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation, 90, 564570.
  • Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 43574363.
  • Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E.J., Carter, C., Bahceci, E., Young, N.S. & Barrett, A.J. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 94, 32343241.
  • Cornely, O.A., Maertens, J., Winston, D.J., Perfect, J., Ullmann, A.J., Walsh, T.J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.T., Petrini, M., Hardalo, C., Suresh, R. & Angulo-Gonzalez, D. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England Journal of Medicine, 356, 348359.
  • Curtis, R.E., Travis, L.B., Rowlings, P.A., Socie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H.J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F. Jr & Deeg, H.J. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 94, 22082216.
  • Deeg, H.J. & Sandmaier, B.M. (2010) Who is fit for allogeneic transplantation? Blood, 116, 47624770.
  • Deeg, H.J., Maris, M.B., Scott, B.L. & Warren, E.H. (2006) Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia, 20, 17011705.
  • Dodero, A., Crocchiolo, R., Patriarca, F., Miceli, R., Castagna, L., Ciceri, F., Bramanti, S., Frungillo, N., Milani, R., Crippa, F., Fallanca, F., Englaro, E. & Corradini, P. (2010) Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer, 116, 50015011.
  • Flomenberg, N., Baxter-Lowe, L.A., Confer, D., Fernandez-Vina, M., Filipovich, A., Horowitz, M., Hurley, C., Kollman, C., Anasetti, C., Noreen, H., Begovich, A., Hildebrand, W., Petersdorf, E., Schmeckpeper, B., Setterholm, M., Trachtenberg, E., Williams, T., Yunis, E. & Weisdorf, D. (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood, 104, 19231930.
  • Gahrton, G. & Bjorkstrand, B. (2000) Progress in haematopoietic stem cell transplantation for multiple myeloma. Journal of Internal Medicine, 248, 185201.
  • Gratama, J.W., Boeckh, M., Nakamura, R., Cornelissen, J.J., Brooimans, R.A., Zaia, J.A., Forman, S.J., Gaal, K., Bray, K.R., Gasior, G.H., Boyce, C.S., Sullivan, L.A. & Southwick, P.C. (2010) Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood, 116, 16551662.
  • Gratwohl, A., Brand, R., Niederwieser, D., Baldomero, H., Chabannon, C., Cornelissen, J., De Witte, T., Ljungman, P., McDonald, F., McGrath, E., Passweg, J., Peters, C., Rocha, V., Slaper-Cortenbach, I., Sureda, A., Tichelli, A. & Apperley, J. (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. Journal of Clinical Oncology, 29, 19801986.
  • Green, M.L., Leisenring, W., Stachel, D., Pergam, S.A., Sandmaier, B.M., Wald, A., Corey, L. & Boeckh, M. (2012) Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 18, 16871699.
  • Hale, G. & Waldmann, H. (1998) Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood, 91, 30793083.
  • Hart, D.P., Avivi, I., Thomson, K.J., Peggs, K.S., Morris, E.C., Goldstone, A.H., Linch, D.C., Ell, P.J., Bomanji, J.B. & Mackinnon, S. (2005) Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. British Journal of Haematology, 128, 824829.
  • Hebart, H., Lengerke, C., Ljungman, P., Paya, C.V., Klingebiel, T., Loeffler, J., Pfaffenrath, S., Lewensohn-Fuchs, I., Barkholt, L., Tomiuk, J., Meisner, C., Lunenberg, J., Top, B., Razonable, R.R., Patel, R., Litzow, M.R., Jahn, G. & Einsele, H. (2011) Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT. Bone Marrow Transplantation, 46, 408415.
  • Hoegh-Petersen, M., Goodyear, D., Geddes, M.N., Liu, S., Ugarte-Torres, A., Liu, Y., Walker, J.T., Fonseca, K., Daly, A., Duggan, P., Stewart, D., Russell, J.A. & Storek, J. (2011) High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplantation, 46, 11041112.
  • Holman, C.J., Karger, A.B., Mullan, B.D., Brundage, R.C. & Balfour, H.H. Jr (2012) Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clinical Transplantation, 26, 741747.
  • Johnston, P.B., Wiseman, G.A. & Micallef, I.N. (2008) Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma. Bone Marrow Transplantation, 41, 919925.
  • Kampmann, B., Cubitt, D., Walls, T., Naik, P., Depala, M., Samarasinghe, S., Robson, D., Hassan, A., Rao, K., Gaspar, H., Davies, G., Jones, A., Cale, C., Gilmour, K., Real, M., Foo, M., Bennett-Rees, N., Hewitt, A., Amrolia, P. & Veys, P. (2005) Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. British Journal of Haematology, 130, 595603.
  • Lambert, J.R., Bomanji, J.B., Peggs, K.S., Thomson, K.J., Chakraverty, R.K., Fielding, A.K., Kottaridis, P.D., Roughton, M., Morris, E.C., Goldstone, A.H., Linch, D.C., Ell, P.J. & Mackinnon, S. (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 115, 27632768.
  • Lee, S.J., Klein, J., Haagenson, M., Baxter-Lowe, L.A., Confer, D.L., Eapen, M., Fernandez-Vina, M., Flomenberg, N., Horowitz, M., Hurley, C.K., Noreen, H., Oudshoorn, M., Petersdorf, E., Setterholm, M., Spellman, S., Weisdorf, D., Williams, T.M. & Anasetti, C. (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood, 110, 45764583.
  • Lim, Z.Y., Pearce, L., Ho, A.Y., Barber, L., Ingram, W., Usai, M., Tobal, K., Devereux, S., Pagliuca, A. & Mufti, G.J. (2007) Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. British Journal of Haematology, 138, 517526.
  • Luznik, L., O'Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., Gooley, T.A., Piantadosi, S., Kaup, M., Ambinder, R.F., Huff, C.A., Matsui, W., Bolanos-Meade, J., Borrello, I., Powell, J.D., Harrington, E., Warnock, S., Flowers, M., Brodsky, R.A., Sandmaier, B.M., Storb, R.F., Jones, R.J. & Fuchs, E.J. (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation, 14, 641650.
  • Mackinnon, S., Barnett, L., Heller, G. & O'Reilly, R.J. (1994) Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood, 83, 34093416.
  • Marks, D.I., Pagliuca, A., Kibbler, C.C., Glasmacher, A., Heussel, C.P., Kantecki, M., Miller, P.J., Ribaud, P., Schlamm, H.T., Solano, C. & Cook, G. (2011) Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. British Journal of Haematology, 155, 318327.
  • Mead, A.J., Thomson, K.J., Morris, E.C., Mohamedbhai, S., Denovan, S., Orti, G., Fielding, A.K., Kottaridis, P.D., Hough, R., Chakraverty, R., Linch, D.C., Mackinnon, S. & Peggs, K.S. (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 115, 51475153.
  • Moreira, R.K., Norton, C., Rosado, F.N., Cohen, C. & Nolte, F. (2010) Histopathologically documented gastrointestinal cytomegalovirus infection in immunosuppressed patients: clinicopathologic analysis with serum quantitative PCR correlation. International Journal of Medicine and Medical Sciences, 2, 4959.
  • Morrissey, C.O., Chen, S.C., Sorrell, T.C., Milliken, S., Bardy, P.G., Bradstock, K.F., Szer, J., Halliday, C.L., Gilroy, N.M., Moore, J., Schwarer, A.P., Guy, S., Bajel, A., Tramontana, A.R., Spelman, T. & Slavin, M.A. (2013) Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. The Lancet Infectious Diseases, 13, 519528.
  • Nikolousis, E., Robinson, S., Nagra, S., Brookes, C., Kinsella, F., Tauro, S., Jeffries, S., Griffiths, M., Mahendra, P., Cook, M., Paneesha, S., Lovell, R., Kishore, B., Chaganti, S., Malladi, R., Raghavan, M., Moss, P., Milligan, D. & Craddock, C. (2013) Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. Leukemia Research, 37, 561565.
  • Peggs, K.S., Banerjee, L., Thomson, K. & Mackinnon, S. (2003a) Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion. Bone Marrow Transplantation, 31, 725726.
  • Peggs, K.S., Verfuerth, S., Pizzey, A., Khan, N., Guiver, M., Moss, P.A. & Mackinnon, S. (2003b) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362, 13751377.
  • Peggs, K.S., Verfuerth, S., Pizzey, A., Chow, S.L., Thomson, K. & Mackinnon, S. (2009) Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clinical Infectious Diseases, 49, 18511860.
  • Peggs, K.S., Thomson, K., Samuel, E., Dyer, G., Armoogum, J., Chakraverty, R., Pang, K., Mackinnon, S. & Lowdell, M.W. (2011a) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clinical Infectious Diseases, 52, 4957.
  • Peggs, K.S., Kayani, I., Edwards, N., Kottaridis, P., Goldstone, A.H., Linch, D.C., Hough, R., Morris, E.C., Fielding, A., Chakraverty, R., Thomson, K.J. & Mackinnon, S. (2011b) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 29, 971978.
  • Perez-Simon, J.A., Caballero, D., Diez-Campelo, M., Lopez-Perez, R., Mateos, G., Canizo, C., Vazquez, L., Vidriales, B., Mateos, M.V., Gonzalez, M. & San Miguel, J.F. (2002) Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia, 16, 14231431.
  • Petersdorf, E.W., Gooley, T., Malkki, M. & Horowitz, M. (2007) Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens, 69(Suppl. 1), 2530.
  • Poulou, L.S., Thanos, L. & Ziakas, P.D. (2010) Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. European Journal of Nuclear Medicine and Molecular Imaging, 37, 156162.
  • Rettinger, E., Willasch, A.M., Kreyenberg, H., Borkhardt, A., Holter, W., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M.H., Schlegel, P.G., Klingebiel, T. & Bader, P. (2011) Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood, 118, 56815688.
  • Richardson, S.E., Khan, I., Rawstron, A., Sudak, J., Edwards, N., Verfuerth, S., Fielding, A.K., Goldstone, A., Kottaridis, P., Morris, E., Benjamin, R., Peggs, K.S., Thomson, K.J., Vandenberghe, E., Mackinnon, S. & Chakraverty, R. (2013) Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology, 160, 640648.
  • Rosenow, F., Berkemeier, A., Krug, U., Muller-Tidow, C., Gerss, J., Silling, G., Groth, C., Wieacker, P., Bogdanova, N., Mesters, R., Buchner, T., Kienast, J., Berdel, W.E. & Stelljes, M. (2013) CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplantation, doi: 10.1038/bmt.2013.2.
  • Schmitt, A., Tonn, T., Busch, D.H., Grigoleit, G.U., Einsele, H., Odendahl, M., Germeroth, L., Ringhoffer, M., Ringhoffer, S., Wiesneth, M., Greiner, J., Michel, D., Mertens, T., Rojewski, M., Marx, M., von Harsdorf, S., Dohner, H., Seifried, E., Bunjes, D. & Schmitt, M. (2010) Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion, 51, 591599.
  • Shaw, B.E., Russell, N.H., Devereux, S., Das-Gupta, E., Mackinnon, S., Madrigal, J.A., Pagliuca, A., Mufti, G.J. & Byrne, J.L. (2005) The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica, 90, 15621569.
  • Shaw, B.E., Arguello, R., Garcia-Sepulveda, C.A. & Madrigal, J.A. (2010) The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology, 150, 251258.
  • Sive, J.I., Thomson, K.J., Morris, E.C., Ward, K.N. & Peggs, K.S. (2012) Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clinical Infectious Diseases, 55, 13621370.
  • Thomson, K.J., Morris, E.C., Milligan, D., Parker, A.N., Hunter, A.E., Cook, G., Bloor, A.J., Clark, F., Kazmi, M., Linch, D.C., Chakraverty, R., Peggs, K.S. & Mackinnon, S. (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. Journal of Clinical Oncology, 28, 36953700.
  • Thomson, K.J., Kayani, I., Ardeshna, K., Morris, E.C., Hough, R., Virchis, A., Goldstone, A.H., Linch, D.C. & Peggs, K.S. (2013) A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia, 27, 14191422.
  • Tiercy, J.M., Passweg, J., Van Biezen, A., Zander, A., Kroger, N., Gratwohl, A., Chapuis, B., Helg, C., Brinch, L., Cornelissen, J., Oudshoorn, M., Ruutu, T., Volin, L., Niederwieser, D. & Roosnek, E. (2004) Isolated HLA-C mismatches in unrelated donor transplantation for CML. Bone Marrow Transplantation, 34, 249255.
  • Van Rhee, F., Lin, F., Cullis, J.O., Spencer, A., Cross, N.C., Chase, A., Garicochea, B., Bungey, J., Barrett, J. & Goldman, J.M. (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood, 83, 33773383.
  • Walter, E.A., Greenberg, P.D., Gilbert, M.J., Finch, R.J., Watanabe, K.S., Thomas, E.D. & Riddell, S.R. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. The New England Journal of Medicine, 333, 10381044.
  • Zandvliet, M.L., van Liempt, E., Jedema, I., Veltrop-Duits, L.A., Willemze, R., Guchelaar, H.J., Falkenburg, J.H. & Meij, P. (2010) Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp 65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy, 12, 933944.